|
|
|
|
|
|
by hammock
1625 days ago
|
|
|
>The -mabs are often denied because they really are expensive to make. Source? According to the HHS via Washington Post[1], many doses of monoclonal antibodies have already been made, but only 20% of those distributed have been used, with 80% sitting on a shelf. The article suggests a few reasons for the lack of use, but it does not mention cost to make them. [1]https://archive.fo/IHK4J |
|
|